PLX
Protalix BioTherapeutics, Inc.
NYSE AmericanUSDEQUITY
Healthcare
DELAYED
Buy
+53/100
Last price
2.73
▲ 0.02 (0.74%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
2.71
Day high
2.76
Day low
2.65
Volume
934.72K
Market cap
$219.96M
P/E (TTM)
11.87
52W range
1.60 – 3.19
Trailing performance
Returnvs SPY
1W
+1.49%
-0.5%
1M
+2.25%
+1.1%
3M
+14.71%
+10.2%
6M
+24.66%
+6.5%
YTD
+51.67%
+37.4%
1Y
+12.35%
-4.1%
3Y
+64.46%
-17.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PLX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.12M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Dec 19, 25 | BASHAN DROR Chief Executive Officer |
BUY | 56.00K | $101.36K | Direct |
| Nov 18, 25 | BAR SHALEV AMOS Director |
SELL | 168 | $314 | Direct |
| Sep 3, 25 | MELINCOFF GWEN A Director |
STOCK | 7.50K | $0 | Indirect |
| Sep 3, 25 | BAR SHALEV AMOS Director |
STOCK | 7.50K | $0 | Indirect |
| Sep 3, 25 | BOUDES POL F Director |
STOCK | 7.50K | $0 | Indirect |
| Sep 3, 25 | SCHWARTZ AHARON Director |
STOCK | 7.50K | $0 | Indirect |
| Sep 3, 25 | NAOS YARON Officer |
STOCK | 25.00K | $0 | Indirect |
| Sep 3, 25 | BASHAN DROR Chief Executive Officer |
STOCK | 195.00K | $0 | Indirect |
| Sep 3, 25 | FORSTER ELIOT Director |
STOCK | 7.50K | $0 | Indirect |
| Sep 3, 25 | BEN ZVI SHMUEL Director |
STOCK | 7.50K | $0 | Indirect |
| Sep 3, 25 | ELZE CHRISTIAN Director |
STOCK | 7.50K | $0 | Indirect |
| Jun 10, 25 | SCHWARTZ AHARON Director |
BUY | 129.00K | $205.88K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAR SHALEV AMOS |
Director | 7.50K | Sale |
BASHAN DROR |
Chief Executive Officer | 2.53M | Purchase |
BEN ZVI SHMUEL |
Director | — | Stock Award(Grant) |
BOUDES POL F |
Director | — | Stock Award(Grant) |
ELZE CHRISTIAN |
Director | — | Stock Award(Grant) |
FORSTER ELIOT |
Director | — | Stock Award(Grant) |
MELINCOFF GWEN A |
Director | — | Stock Award(Grant) |
NAOS YARON |
Officer | — | Stock Award(Grant) |
SCHWARTZ AHARON |
Director | — | Stock Award(Grant) |
Fundamentals
Market cap$219.96M
Enterprise value$188.51M
Revenue (TTM)$80.62M
Gross profit$36.90M
EBITDA$24.86M
Net income$18.95M
EPS (TTM)$0.23
Free cash flow$2.99M
Total cash$40.66M
Total debt$9.21M
Book value / share$0.89
Shares outstanding80.57M
Float77.45M
Short % of float3.72%
Dividend yield0.00%
Beta (5Y)-0.09
Valuation & profitability ratios
Trailing P/E11.87
Forward P/E4.40
PEG ratio—
Price / sales—
Price / book3.08
EV / revenue2.34
EV / EBITDA7.58
Gross margin45.77%
Operating margin23.48%
Profit margin23.50%
Return on equity31.24%
Return on assets15.42%
Debt / equity12.89
Current ratio2.94
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $52.74M | $53.40M | $65.49M | $47.64M | -1.2% |
| Operating revenue | $52.74M | $53.40M | $65.49M | $47.64M | -1.2% |
| Cost of revenue | $26.99M | $24.32M | $22.98M | $19.59M | +11.0% |
| Gross profit | $25.75M | $29.08M | $42.51M | $28.05M | -11.4% |
| Research & development | $19.57M | $12.97M | $17.09M | $29.35M | +50.9% |
| Selling, general & admin | $11.68M | $12.19M | $14.96M | $11.71M | -4.2% |
| Total operating expense | $31.25M | $25.16M | $32.05M | $41.06M | +24.2% |
| Operating income | -$5.50M | $3.92M | $10.46M | -$13.01M | -240.4% |
| Net interest income | -$108.00K | $237.00K | -$1.89M | -$1.38M | -145.6% |
| Pre-tax income | -$5.61M | $4.15M | $8.57M | -$14.40M | -235.0% |
| Tax provision | $996.00K | $1.22M | $254.00K | $530.00K | -18.5% |
| Net income | -$6.60M | $2.93M | $8.31M | -$14.93M | -325.2% |
| Net income to common | -$6.60M | $2.93M | $8.31M | -$14.93M | -325.2% |
| Basic EPS | -0.08 | 0.04 | 0.12 | -0.31 | -300.0% |
| Diluted EPS | -0.08 | 0.04 | 0.09 | -0.31 | -300.0% |
| EBIT | -$4.42M | $5.22M | $11.75M | -$11.87M | -184.7% |
| EBITDA | -$2.95M | $6.52M | $12.94M | -$10.78M | -145.3% |
| Basic shares | 78.55M | 72.53M | 67.51M | 48.47M | +8.3% |
| Diluted shares | 78.55M | 81.06M | 82.42M | 48.47M | -3.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $14.68M | $19.76M | $23.63M | $17.11M | — | -25.7% |
| Cash & short-term investments | $30.27M | $34.83M | $44.56M | $22.18M | — | -13.1% |
| Accounts receivable | $8.84M | $2.91M | $5.27M | $4.59M | — | +203.9% |
| Inventory | $25.73M | $21.24M | $19.05M | $16.80M | — | +21.1% |
| Total current assets | $66.67M | $60.08M | $69.93M | $44.88M | — | +11.0% |
| Property, plant & equipment | $12.58M | $10.02M | $10.88M | $9.64M | — | +25.5% |
| Total assets | $82.35M | $73.42M | $84.43M | $55.79M | — | +12.2% |
| Total current liabilities | $26.52M | $25.62M | $45.53M | $32.43M | — | +3.5% |
| Current debt | — | — | $20.25M | — | — | — |
| Long-term debt | — | — | — | $28.19M | $27.89M | — |
| Total debt | $8.32M | $5.53M | $26.28M | $33.47M | — | +50.6% |
| Total liabilities | $34.12M | $30.21M | $50.87M | $66.43M | — | +12.9% |
| Retained earnings | -$385.00M | -$378.39M | -$381.55M | -$389.86M | — | -1.7% |
| Shareholder equity | $48.23M | $43.21M | $33.57M | -$10.64M | — | +11.6% |
| Working capital | $40.16M | $34.46M | $24.40M | $12.45M | — | +16.5% |
| Net tangible assets | $48.23M | $43.21M | $33.57M | -$10.64M | — | +11.6% |
| Shares issued | 80.43M | 75.85M | 72.95M | 53.79M | — | +6.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$6.60M | $2.93M | $8.31M | -$14.93M | -325.2% |
| Depreciation & amortisation | $1.47M | $1.30M | $1.19M | $1.09M | +12.3% |
| Stock-based compensation | $2.30M | $3.25M | $3.45M | $2.08M | -29.4% |
| Change in working capital | -$10.10M | $811.00K | -$10.54M | -$12.02M | -1,345.3% |
| Operating cash flow | -$11.99M | $8.67M | -$1.32M | -$25.00M | -238.3% |
| Capital expenditure | -$1.64M | -$1.28M | -$1.15M | -$628.00K | -27.8% |
| Investing cash flow | -$2.37M | $4.22M | -$16.71M | -$5.04M | -156.1% |
| Financing cash flow | $9.33M | -$16.79M | $24.67M | $8.24M | +155.5% |
| Free cash flow | -$13.63M | $7.39M | -$2.47M | -$25.63M | -284.4% |
| End cash position | $14.68M | $19.76M | $23.63M | $17.11M | -25.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $19.90M | $33.75M | $9.12M | $17.85M | $15.66M | — | -41.0% |
| Operating revenue | $19.90M | $33.75M | $9.12M | $17.85M | $15.66M | — | -41.0% |
| Cost of revenue | $7.76M | $4.13M | $4.62M | $8.32M | $5.87M | — | +88.1% |
| Gross profit | $12.13M | $29.62M | $4.50M | $9.53M | $9.79M | — | -59.0% |
| Research & development | $4.35M | $5.43M | $5.63M | $4.47M | $5.99M | — | -19.8% |
| Selling, general & admin | $3.11M | $3.05M | $3.53M | $2.93M | $2.62M | — | +2.0% |
| Total operating expense | $7.46M | $8.48M | $9.16M | $7.40M | $8.62M | — | -12.0% |
| Operating income | $4.67M | $21.15M | -$4.66M | $2.13M | $1.17M | — | -77.9% |
| Net interest income | $188.00K | -$5.00K | -$118.00K | $108.00K | -$511.00K | — | +3,860.0% |
| Pre-tax income | $4.86M | $21.14M | -$4.78M | $2.24M | $661.00K | — | -77.0% |
| Tax provision | $1.08M | $2.82M | $728.00K | -$116.00K | $497.00K | — | -61.7% |
| Net income | $3.78M | $18.32M | -$5.50M | $2.35M | $164.00K | — | -79.4% |
| Net income to common | $3.78M | $18.32M | -$5.50M | $2.35M | $164.00K | — | -79.4% |
| Basic EPS | 0.05 | 0.23 | — | 0.03 | 0.00 | -0.05 | -78.3% |
| Diluted EPS | 0.05 | 0.22 | — | 0.03 | 0.00 | -0.05 | -77.3% |
| EBIT | $5.35M | $21.33M | -$4.39M | $2.42M | $1.44M | — | -74.9% |
| EBITDA | $5.76M | $21.74M | -$4.01M | $2.79M | $1.80M | — | -73.5% |
| Basic shares | 79.99M | 79.85M | — | 79.28M | 78.66M | 76.61M | +0.2% |
| Diluted shares | 82.56M | 83.05M | — | 80.81M | 81.27M | 76.61M | -0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.42M | $41.00M | $14.68M | $13.65M | $17.89M | -33.1% |
| Cash & short-term investments | $40.66M | $51.08M | $30.27M | $29.37M | $33.40M | -20.4% |
| Accounts receivable | $16.50M | $2.94M | $8.84M | $14.43M | $9.44M | +461.5% |
| Inventory | $32.29M | $30.47M | $25.73M | $21.25M | $21.13M | +6.0% |
| Total current assets | $92.22M | $86.36M | $66.67M | $66.50M | $65.48M | +6.8% |
| Property, plant & equipment | $13.64M | $12.95M | $12.58M | $12.53M | $9.74M | +5.4% |
| Total assets | $110.34M | $102.34M | $82.35M | $82.26M | $78.49M | +7.8% |
| Total current liabilities | $31.39M | $27.39M | $26.52M | $21.95M | $24.09M | +14.6% |
| Total debt | $9.21M | $8.48M | $8.32M | $8.18M | $5.35M | +8.6% |
| Total liabilities | $38.93M | $35.11M | $34.12M | $29.36M | $28.58M | +10.9% |
| Retained earnings | -$362.90M | -$366.68M | -$385.00M | -$379.49M | -$381.85M | +1.0% |
| Shareholder equity | $71.40M | $67.23M | $48.23M | $52.91M | $49.90M | +6.2% |
| Working capital | $60.83M | $58.97M | $40.16M | $44.56M | $41.39M | +3.2% |
| Net tangible assets | $71.40M | $67.23M | $48.23M | $52.91M | $49.90M | +6.2% |
| Shares issued | 80.57M | 80.57M | 80.43M | 80.34M | 79.73M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $3.78M | $18.32M | -$5.50M | $2.35M | $164.00K | -79.4% |
| Depreciation & amortisation | $406.00K | $404.00K | $387.00K | $372.00K | $360.00K | +0.5% |
| Stock-based compensation | $398.00K | $532.00K | $732.00K | $598.00K | $427.00K | -25.2% |
| Change in working capital | -$15.56M | $2.54M | $5.78M | -$7.14M | -$6.90M | -713.0% |
| Operating cash flow | -$10.40M | $22.02M | $2.03M | -$3.73M | -$5.23M | -147.2% |
| Capital expenditure | -$593.00K | -$761.00K | -$403.00K | -$498.00K | -$431.00K | +22.1% |
| Investing cash flow | -$3.63M | $4.22M | -$1.11M | -$504.00K | -$438.00K | -186.1% |
| Financing cash flow | $0 | $150.00K | $146.00K | $0 | $4.10M | -100.0% |
| Free cash flow | -$10.99M | $21.26M | $1.63M | -$4.23M | -$5.66M | -151.7% |
| End cash position | $27.42M | $41.00M | $14.68M | $13.65M | $17.89M | -33.1% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
-8.4% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
1
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.01 | 0.05 | +600.0% |
| Mar 2026 | -0.01 | 0.22 | +2,300.0% |
| Dec 2025 | 0.01 | -0.07 | -1,500.0% |
| Sep 2025 | 0.06 | 0.03 | -45.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.02 | 2 | $12.41M | -30.5% |
| Next quarter | -0.02 | 2 | $16.11M | +76.6% |
| Current year | 0.24 | 2 | $82.16M | +55.8% |
| Next year | 0.05 | 2 | $66.48M | -19.1% |
Analyst targets & ownership
Mean target$11.00
High target$12.00
Low target$10.00
Implied upside302.93%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders3.88%
Held by institutions18.42%
Institutions holding136
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.72
+0.22% from price
SMA 20
2.72
+0.42% from price
SMA 50
2.55
+6.96% from price
SMA 100
2.37
+15.35% from price
SMA 200
2.34
+16.48% from price
EMA 12
2.71
+0.57% from price
EMA 26
2.67
+2.26% from price
EMA 50
2.58
+5.82% from price
RSI (14)
55.7
Neutral
MACD (12,26,9)
0.04
Hist -0.01
ATR (14)
0.09
3.40% of price
Realised vol 30D
34.8%
Annualised
Bollinger upper
2.81
20, 2σ
Bollinger lower
2.62
20, 2σ
50 / 200 cross
Golden
2.55 vs 2.34
Trend bias
Above 200
+16.48%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.17
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
34.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-39.7%
Peak to trough
Max drawdown 5Y
-73.2%
Peak to trough
ATR 14
0.09
3.40% of price
Beta (reported)
-0.09
5Y monthly, from filing
Short interest
Shares short
2.88M
Prior 3.58M
Change vs prior
-19.5%
Shorts covering
% of float
3.72%
Normal
% of shares out
3.57%
Against total outstanding
Days to cover
4.1
Liquid
Float
77.45M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 19, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 21, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 3, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 14, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 31, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateDec 20, 2019
Last split1:10
Split dateDec 20, 2019
SEC filings
Offering Registrations
S-8 · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-06-25
Corporate Changes & Voting Matters
8-K · 2026-05-21
Periodic Financial Reports
10-Q · 2026-05-13
Proxy Statements
DEF 14A · 2026-04-30
Periodic Financial Reports
10-K · 2026-03-18
Corporate Changes & Voting Matters
8-K · 2026-03-09
Corporate Changes & Voting Matters
8-K · 2026-02-11
Headlines
Netflix downgraded, SanDisk initiated: Wall Street's top analyst calls
The Fly · 15d ago
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
PR Newswire · 29d ago
Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · 54d ago
PLX: Elfabrio Estimates Up
Zacks Small Cap Research · 55d ago
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ...
GuruFocus.com · 55d ago
Protalix: Q2 Earnings Snapshot
Associated Press · 56d ago
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
PR Newswire · 56d ago
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
PR Newswire · 63d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.